Close Menu

NEW YORK – Castle Biosciences reported after the close of the market on Monday that its fourth quarter revenues fell 2 percent year over year.

For the three months ended Dec. 31, 2020, the skin cancer diagnostics company reported revenues of $17.3 million, down from $17.6 million a year earlier, but beating the average Wall Street estimate of $15.7 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.